NCT05662449

Brief Summary

The investigators aim to evaluate the fixation of the ankle syndesmosis in appropriate ankle fractures with bioabsorbable screws. Ankle fractures are common, and a proportion of them involve both fracture of the bone and also disruption of the syndesmosis, a strong ligamentous complex connecting the distal fibula and tibia. If left without fixation this causes a high incidence of pain and early arthritis. The most common technique for fixation of this syndesmosis involves the use of the same type of metal screws used to fix the fractured bones. As the syndesmosis permits small degrees of movement in normal subjects, fixation of this with metal usually leads to screw breakage and, or pain. It is common practice to remove these screws after a period of time once the syndesmosis has healed in the correct position. Bioabsorbable screws have the advantage of allowing small increments of movement, and also resorb naturally therefore do not have to be removed with a second surgical procedure. They are used in other centres worldwide, and the investigators therefore seek to evaluate syndesmosis fixation with them in their unit. The investigators would aim to recruit patients who have a syndesmotic injury requiring fixation, and who can consent to participating. They would undergo an identical surgical procedure to the standard current practice, apart from using a bioabsorbable screw in exchange for the metallic screw for syndesmosis fixation. All other components would remain unchanged, as would post operative protocol and management. To evaluate the fixation the investigators would use a limited CT scan (equivalent of about 3 months background radiation) after the time of fixation and at one year. This will help to assess the maintenance of reduction of the syndesmosis with time. The investigators would also assess patient reported outcome measures and pain scores, length of procedure and intraoperative radiation levels, weight bearing distribution tests, as well as any complication that may arise.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 8, 2021

Completed
24 days until next milestone

Study Start

First participant enrolled

April 1, 2021

Completed
1.7 years until next milestone

First Posted

Study publicly available on registry

December 22, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

December 22, 2022

Status Verified

December 1, 2022

Enrollment Period

3.8 years

First QC Date

March 8, 2021

Last Update Submit

December 14, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Computerised Tomography (CT) scan syndesmosis

    All patients will undergo focused CT scanning two weeks post operatively and at one year. A customised foot holding device will enable to scan to be taken with both feet in neutral alignment (Evolution supine foot positioner, Vasocare Ltd). Assessment will be made in comparison with the contralateral side to assess reduction of the syndesmosis. Quantitive measurement of reduction will be measured using an established technique from the paper cited below in references.

    Change in reduction between 2 weeks and 1 year post operatively

Secondary Outcomes (9)

  • Surgical Duration

    Intraoperative

  • X- Ray (XR) Radiation exposure time and total dose

    Intraoperative

  • Olerud-Molander Ankle Score (OMAS)

    Pre-operative (baseline), 3 months, 6 months and 1 year post operatively. Absolute values measured as well as change in score over time intervals noted.

  • EQ5D3L (European Quality of Life 5 Dimensions 3 Level Version)

    Pre-operative (baseline), 3 months, 6 months and 1 year post operatively.Absolute values measured as well as change in score over time intervals noted.

  • EQ-5D-3L VAS (European Quality of Life 5 Dimensions 3 Level Version) Health state

    Pre-operative (baseline), 3 months, 6 months and 1 year post operatively.Absolute values measured as well as change in score over time intervals noted.

  • +4 more secondary outcomes

Study Arms (1)

Ankle fracture with syndesmosis injury

Syndesmosis fixation using bioabsorbable screw

Device: Syndesmosis fixation using Activascrew

Interventions

as described prior

Ankle fracture with syndesmosis injury

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Meets above criteria with appropriate ankle fracture

You may qualify if:

  • Patient has a Weber C fibula fracture with or without a medial malleolus fracture and evidence of radiological syndesmotic widening on intra-operative stressing
  • Patient has a Weber B fracture with evidence of syndesmosis widening radiologically on stressing intra-operatively
  • Patient has a maissoneuve type injury with evidence of syndesmotic diastasis
  • Patient mobilises independently, with or without aids.
  • Patient has given formal consent to be involved in the trial and has completed the study consent form
  • Patient is likely to comply with study requirements
  • Patient is over the age of 18 years and under 65 years

You may not qualify if:

  • Immobility
  • Presence of a posterior malleolus fracture involving \>25% of articular surface
  • Open fractures
  • Pathological fractures
  • Other fractures involving the same lower extremity
  • Patient unwilling to give informed consent to be included in the trial
  • Patient has other injuries that would influence the study
  • Any ankle fracture that the treating surgeon feels inappropriate to be included in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aberdeen Royal Infirmary

Aberdeen, AB25 2ZN, United Kingdom

RECRUITING

Related Publications (1)

  • Phisitkul P, Ebinger T, Goetz J, Vaseenon T, Marsh JL. Forceps reduction of the syndesmosis in rotational ankle fractures: a cadaveric study. J Bone Joint Surg Am. 2012 Dec 19;94(24):2256-61. doi: 10.2106/JBJS.K.01726.

    PMID: 23318616BACKGROUND

MeSH Terms

Conditions

Ankle InjuriesAnkle FracturesDisease

Condition Hierarchy (Ancestors)

Leg InjuriesWounds and InjuriesFractures, BonePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Alan Johnstone, MBChB FRCS

    NHS Grampian

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mariam Sattar, MBChB(Hons)

CONTACT

Alan Johnstone, MBChB FRCS

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 8, 2021

First Posted

December 22, 2022

Study Start

April 1, 2021

Primary Completion

December 31, 2024

Study Completion

July 1, 2025

Last Updated

December 22, 2022

Record last verified: 2022-12

Data Sharing

IPD Sharing
Will not share

Locations